In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.
--------
Question: SECTION 1. PARTICIPATION OF TAIWAN IN THE WORLD HEALTH ORGANIZATION.

    (a) Findings.--Congress makes the following findings:
            (1) The World Health Organization (WHO) is a specialized 
        agency of the United Nations, charged with coordinating health 
        efforts within the United Nations system. The World Health 
        Assembly (WHA) is the decision-making body of the WHO, which 
        convenes annually in May to set the policies and priorities of 
        the organization. Statehood is not a requirement for attendance 
        at the WHA, and numerous observers, including non-members and 
        non-governmental organizations, attended the most recent WHA in 
        May 2017.
            (2) Taiwan began seeking to participate in the WHO as an 
        observer in 1997. In 2009, with strong support from successive 
        United States Administrations, Congress, and like-minded WHO 
        Member States, and during a period of improved Cross-Strait 
        relations, Taiwan received an invitation to attend the WHA as 
        an observer under the name ``Chinese Taipei''. Taiwan received 
        the same invitation each year until 2016, when following the 
        election of President Tsai-Ing Wen of the Democratic 
        Progressive Party, Taiwan's engagement in the international 
        community began facing increased resistance from the People's 
        Republic of China (PRC). Taiwan's invitation to the 2016 WHA 
        was received late and included new language conditioning 
        Taiwan's participation on the PRC's ``one China principle''. In 
        2017, Taiwan did not receive an invitation to the WHA.
            (3) Taiwan remains a model contributor to world health, 
        having provided financial and technical assistance to respond 
        to numerous global health challenges. Taiwan has invested over 
        $6 billion in international medical and humanitarian aid 
        efforts impacting over 80 countries since 1996. In 2014, Taiwan 
        responded to the Ebola crisis by donating $1 million and 
        providing 100,000 sets of personal protective equipment. 
        Through the Global Cooperation and Training Framework, the 
        United States and Taiwan have jointly conducted training 
        programs for experts to combat MERS, Dengue Fever, and Zika. 
        These diseases know no borders, and Taiwan's needless exclusion 
        from global health cooperation increases the dangers presented 
        by global pandemics.
            (4) Taiwan's international engagement has faced increased 
        resistance from the PRC. Taiwan was not invited to the 2016 
        Assembly of the International Civil Aviation Organization 
        (ICAO), despite participating as a guest at the organization's 
        prior summit in 2013. Taiwan's request to participate in the 
        2016 General Assembly of the International Criminal Police 
        Organization (INTERPOL) was also rejected. In May 2017, PRC 
        delegates disrupted a meeting of the Kimberley Process on 
        conflict diamonds held in Perth, Australia, until delegates 
        from Taiwan were asked to leave. In June 2017, the Republic of 
        Panama granted diplomatic recognition to the PRC, terminating a 
        longstanding diplomatic relationship with Taiwan.
            (5) Congress has established a policy of support for 
        Taiwan's participation in international bodies that address 
        shared transnational challenges, particularly in the WHO. 
        Congress passed H.R. 1794 in the 106th Congress, H.R. 428 in 
        the 107th Congress, and S. 2092 in the 108th Congress to direct 
        the Secretary of State to establish a strategy for, and to 
        report annually to Congress on, efforts to obtain observer 
        status for Taiwan at the WHA. Congress also passed H.R. 1151 in 
        the 113th Congress, directing the Secretary to report on a 
        strategy to gain observer status for Taiwan at the ICAO 
        Assembly, and H.R. 1853 in the 114th Congress, directing the 
        Secretary to report on a strategy to gain observer status for 
        Taiwan at the INTERPOL Assembly. However, in 2016 Taiwan did 
        not receive invitations to attend any of these events as an 
        observer.
    (b) Augmentation of Report Concerning the Participation of Taiwan 
in the World Health Organization.--
            (1) In general.--Subsection (c) of section 1 of Public Law 
        108-235 (118 Stat. 656) is amended by adding at the end the 
        following new paragraph:
            ``(3) An account of the changes and improvements the 
        Secretary of State has made to the United States plan to 
        endorse and obtain observer status for Taiwan at the World 
        Health Assembly, following any annual meetings of the World 
        Health Assembly at which Taiwan did not obtain observer 
        status.''.
            (2) Effective date.--The amendment made by paragraph (1) 
        shall take effect and apply beginning with the first report 
        required under subsection


              

         (c) of section 1 of Public Law 108-235 that is submitted after 
        the date of the enactment of this Act.

            Passed the House of Representatives January 9, 2018.

            Attest:

                                                 KAREN L. HAAS,

                                                                 Clerk.

Answer:  (Sec. 1) This bill requires the annual reports submitted by the Department of State to Congress concerning the U.S. plan to endorse and obtain observer status for Taiwan at the annual summit of the World Health Assembly (WHA) held by the World Health Organization in Geneva, Switzerland, to include an account of the changes and improvements that the State Department has made to such plan following any annual meetings of the WHA at which Taiwan did not obtain such status. 


Question: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Genetically Engineered Food Right-
to-Know Act''.

SEC. 2. PURPOSE AND FINDINGS.

    (a) Purpose.--The purpose of this Act is to establish a consistent 
and enforceable standard for labeling of foods produced using genetic 
engineering, including fish, thereby providing consumers with knowledge 
of how their food is produced.
    (b) Findings.--Congress finds that--
            (1) the process of genetically engineering food organisms 
        results in material changes to food derived from those 
        organisms;
            (2) the Food and Drug Administration requires the labeling 
        of more than 3,000 ingredients, additives, and processes;
            (3) individuals in the United States have a right to know 
        if their food was produced with genetic engineering for a 
        variety of reasons, including health, economic, environmental, 
        religious, and ethical;
            (4) more than 60 countries, including the United Kingdom 
        and all other countries of the European Union, South Korea, 
        Japan, Brazil, Australia, India, China, and other key United 
        States trading partners have laws or regulations mandating 
        disclosure of genetically engineered food on food labels;
            (5) in 2011, Codex Alimentarius, the food standards 
        organization of the United Nations, adopted a text that 
        indicates that governments can decide on whether and how to 
        label foods produced with genetic engineering; and
            (6) mandatory identification of food produced with genetic 
        engineering can be a critical method of preserving the economic 
        value of exports or domestically sensitive markets with 
        labeling requirements for genetically engineered foods.

SEC. 3. AMENDMENTS TO THE FEDERAL FOOD, DRUG, AND COSMETIC ACT.

    (a) In General.--Section 403 of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 343) is amended by adding at the end the 
following:
    ``(z)(1) If it is a food that has been genetically engineered or 
contains 1 or more genetically engineered ingredients, unless such 
information is clearly disclosed, as determined by the Secretary.
    ``(2) This paragraph does not apply to food that--
            ``(A) is served in restaurants or other similar eating 
        establishments, such as cafeterias and carryouts;
            ``(B) is a medical food (as defined in section 5(b) of the 
        Orphan Drug Act);
            ``(C) is a food that would be subject to this paragraph 
        solely because it was produced using a genetically engineered 
        vaccine; or
            ``(D) is a food or processed food that would be subject to 
        this paragraph solely because it includes the use of a 
        genetically engineered processing aid (including yeast) or 
        enzyme.
    ``(3) In this paragraph:
            ``(A) The term `genetic engineering' means a process 
        involving the application of--
                    ``(i) in vitro nucleic acid techniques, including 
                recombinant deoxyribonucleic acid (DNA) and direct 
                injection of nucleic acid into cells or organelles; or
                    ``(ii) fusion of cells beyond the taxonomic family 
                that--
                            ``(I) overcome natural physiological 
                        reproductive or recombinant barriers; and
                            ``(II) are not techniques used in 
                        traditional breeding and selection.
            ``(B) The term `genetically engineered', used with respect 
        to a food, means a material intended for human consumption that 
        is--
                    ``(i) an organism that is produced through the 
                intentional use of genetic engineering; or
                    ``(ii) the progeny of intended sexual or asexual 
                reproduction (or both) of 1 or more organisms that is 
                the product of genetic engineering.
            ``(C) The term `genetically engineered ingredient' means a 
        material that is an ingredient in a food that is derived from 
        any part of an organism that has been genetically engineered, 
        without regard to whether--
                    ``(i) the altered molecular or cellular 
                characteristics of the organism are detectable in the 
                material; and
                    ``(ii) the organism is capable for use as human 
                food.''.
    (b) Guaranty.--
            (1) In general.--Section 303(d) of the Federal Food, Drug, 
        and Cosmetic Act (21 U.S.C. 333(d)) is amended--
                    (A) by striking ``(d)'' and inserting ``(d)(1)''; 
                and
                    (B) by adding at the end the following:
            ``(2)(A) No person shall be subject to the penalties of 
        subsection (a)(1) for a violation of subsection (a), (b), or 
        (c) of section 301 involving food that is misbranded within the 
        meaning of section 403(z) if such person (referred to in this 
        paragraph as the `recipient') establishes a guaranty or 
        undertaking that--
                    ``(i) is signed by, and contains the name and 
                address of, a person residing in the United States from 
                whom the recipient received in good faith the food 
                (including the receipt of seeds to grow raw 
                agricultural commodities); and
                    ``(ii) contains a statement to the effect that the 
                food is not genetically engineered or does not contain 
                a genetically engineered ingredient.
            ``(B) In the case of a recipient who, with respect to a 
        food, establishes a guaranty or undertaking in accordance with 
        subparagraph (A), the exclusion under such subparagraph from 
        being subject to penalties applies to the recipient without 
        regard to the manner in which the recipient uses the food, 
        including whether the recipient is--
                    ``(i) processing the food;
                    ``(ii) using the food as an ingredient in a food 
                product;
                    ``(iii) repacking the food; or
                    ``(iv) growing, raising, or otherwise producing the 
                food.
            ``(C) No person may avoid responsibility or liability for a 
        violation of subsection (a), (b), or (c) of section 301 
        involving food that is misbranded within the meaning of section 
        403(z) by entering into a contract or other agreement that 
        specifies that another person shall bear such responsibility or 
        liability, except that a recipient may require a guaranty or 
        undertaking as described in this subsection.
            ``(D) In this subsection, the terms `genetically 
        engineered' and `genetically engineered ingredient' have the 
        meanings given the terms in section 403(z).''.
            (2) False guaranty.--Section 301(h) of the Federal Food, 
        Drug, and Cosmetic Act (21 U.S.C. 331(h)) is amended by 
        inserting ``or 303(d)(2)'' after ``section 303(c)(2)''.
    (c) Unintended Contamination.--Section 303(d) of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 333(d)), as amended by subsection 
(b), is further amended by adding at the end the following:
            ``(3)(A) No person shall be subject to the penalties of 
        subsection (a)(1) for a violation of subsection (a), (b), or 
        (c) of section 301 involving food that is misbranded within the 
        meaning of section 403(z) if--
                    ``(i) such person is an agricultural producer and 
                the violation occurs because food that is grown, 
                raised, or otherwise produced by such producer, which 
                food does not contain a genetically engineered material 
                and was not produced with a genetically engineered 
                material, is contaminated with a food that contains a 
                genetically engineered material or was produced with a 
                genetically engineered material; and
                    ``(ii) such contamination is not intended by the 
                agricultural producer.
            ``(B) Subparagraph (A) does not apply to an agricultural 
        producer to the extent that the contamination occurs as a 
        result of the negligence of the producer.''.
    (d) Promulgation of Regulations.--Not later than 1 year after the 
date of enactment of this Act, the Secretary shall promulgate proposed 
regulations establishing labeling requirements for compliance in 
accordance with section 403(z) of the Federal Food, Drug, and Cosmetic 
Act, as added by subsection (a).

Answer: Genetically Engineered Food Right-to-Know Act - Amends the Federal Food, Drug, and Cosmetic Act to deem misbranded any food that has been genetically engineered or contains one or more genetically engineered ingredients, unless such information is clearly disclosed. Exempts from this requirement any food that: (1) is served in restaurants or other similar eating establishments, (2) is a medical food, (3) would be subject to such requirement solely because it was produced using a genetically engineered vaccine, or (4) would be subject to such requirement solely because it includes the use of a genetically engineered processing aid (including yeast) or enzyme. Defines &quot;genetically engineered&quot; as a material intended for human consumption that is: (1) an organism produced through the intentional use of genetic engineering, or (2) the progeny of intended sexual or asexual reproduction (or both) of one or more organisms that is the product of genetic engineering. Defines &quot;genetically engineered ingredient&quot; as an ingredient in a food that is derived from any part of an organism that has been genetically engineered, without regard to whether: (1) the altered molecular or cellular characteristics of the organism are detectable in the material, and (2) the organism is capable for use as human food. Excludes from penalties for misbranding of genetically engineered food or ingredients any recipient that establishes a guaranty or undertaking that: (1) is signed by, and contains the name and address of, a person residing in the United States from whom the recipient received the food in good faith (including the receipt of seeds to grow raw agricultural commodities); and (2) contains a statement to the effect that the food is not genetically engineered or does not contain a genetically engineered ingredient. Applies this exclusion from penalties without regard to the manner in which the recipient uses the food. Excludes an agricultural producer also from such penalties when a violation occurs because food the producer has grown, raised, or otherwise produced, which neither contains nor was produced with a genetically engineered material, is subsequently contaminated with a food that does contain or was produced with a genetically engineered material, and the agricultural producer has not intended any such contamination nor was negligent in the matter.


Question: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Equity in Fertility Coverage Act of 
2001''.

SEC. 2. EQUITY IN PROVISION OF PRESCRIPTION DRUG COVERAGE.

    (a) Group Health Plans.--
            (1) Public health service act amendments.--(A) Subpart 2 of 
        part A of title XXVII of the Public Health Service Act is 
        amended by adding at the end the following new section:

``SEC. 2707. EQUITY IN FERTILITY COVERAGE.

    ``(a) In General.--A group health plan, and a health insurance 
issuer offering group health insurance coverage, that provides for 
coverage of impotency medications such as viagra shall also provide 
coverage of fertility treatments.
    ``(b) Construction.--Nothing in this section shall be construed as 
preventing a plan or issuer from--
            ``(1) restricting the drugs for which benefits are provided 
        under the plan or health insurance coverage, or
            ``(2) imposing a limitation on the amount of benefits 
        provided with respect to such coverage or the cost-sharing that 
        may be imposed with respect to such coverage,
so long as such restrictions and limitations are consistent with 
subsection (a).
    ``(c) Notice.--A group health plan under this part shall comply 
with the notice requirement under section 714(c) of the Employee 
Retirement Income Security Act of 1974 with respect to the requirements 
of this section as if such section applied to such plan.''.
            (B) Section 2723(c) of such Act (42 U.S.C. 300gg-23(c)) is 
        amended by striking ``section 2704'' and inserting ``sections 
        2704 and 2707''.
            (2) ERISA amendments.--(A) Subpart B of part 7 of subtitle 
        B of title I of the Employee Retirement Income Security Act of 
        1974 is amended by adding at the end the following new section:

``SEC. 714. EQUITY IN FERTILITY COVERAGE.

    ``(a) In General.--A group health plan, and a health insurance 
issuer offering group health insurance coverage, that provides for 
coverage of impotency medications such as viagra shall also provide 
coverage of fertility treatments.
    ``(b) Construction.--Nothing in this section shall be construed as 
preventing a plan or issuer from--
            ``(1) restricting the drugs for which benefits are provided 
        under the plan or health insurance coverage, or
            ``(2) imposing a limitation on the amount of benefits 
        provided with respect to such coverage or the cost-sharing that 
        may be imposed with respect to such coverage,
so long as such restrictions and limitations are consistent with 
subsection (a).
    ``(c) Notice Under Group Health Plan.--The imposition of the 
requirements of this section shall be treated as a material 
modification in the terms of the plan described in section 102(a)(1), 
for purposes of assuring notice of such requirements under the plan; 
except that the summary description required to be provided under the 
last sentence of section 104(b)(1) with respect to such modification 
shall be provided by not later than 60 days after the first day of the 
first plan year in which such requirements apply.''.
            (B) Section 731(c) of such Act (29 U.S.C. 1191(c)) is 
        amended by striking ``section 711'' and inserting ``sections 
        711 and 714''.
            (C) Section 732(a) of such Act (29 U.S.C. 1191a(a)) is 
        amended by striking ``section 711'' and inserting ``sections 
        711 and 714''.
            (D) The table of contents in section 1 of such Act is 
        amended by inserting after the item relating to section 713 the 
        following new item:

``Sec. 714. Equity in fertility coverage.''.
    (b) Individual Health Insurance.--(1) Part B of title XXVII of the 
Public Health Service Act is amended by inserting after section 2752 
the following new section:

``SEC. 2753. EQUITY IN FERTILITY COVERAGE.

    ``(a) In General.--The provisions of section 2707 (other than 
subsection (c)) shall apply to health insurance coverage offered by a 
health insurance issuer in the individual market in the same manner as 
it applies to health insurance coverage offered by a health insurance 
issuer in connection with a group health plan in the small or large 
group market.
    ``(b) Notice.--A health insurance issuer under this part shall 
comply with the notice requirement under section 714(c) of the Employee 
Retirement Income Security Act of 1974 with respect to the requirements 
referred to in subsection (a) as if such section applied to such issuer 
and such issuer were a group health plan.''.
    (2) Section 2762(b)(2) of such Act (42 U.S.C. 300gg-62(b)(2)) is 
amended by striking ``section 2751'' and inserting ``sections 2751 and 
2753''.
    (c) FEHBP.--Section 8902 of title 5, United States Code, is amended 
by adding at the end the following new subsection:
    ``(p) A contract may not be made or a plan approved which does not 
comply with the requirements of section 2753 of the Public Health 
Service Act.''.
    (d) Effective Dates.--(1) The amendments made by subsection (a) 
shall apply with respect to group health plans for plan years beginning 
on or after January 1, 2002.
    (2) The amendments made by subsection (b) shall apply with respect 
to health insurance coverage offered, sold, issued, renewed, in effect, 
or operated in the individual market on or after January 1, 2002.
    (3) The amendment made by subsection (c) shall apply with respect 
to contracts for periods beginning on and after January 1, 2002.
    (e) Coordinated Regulations.--Section 104(1) of Health Insurance 
Portability and Accountability Act of 1996 is amended by striking 
``this subtitle (and the amendments made by this subtitle and section 
401)'' and inserting ``the provisions of part 7 of subtitle B of title 
I of the Employee Retirement Income Security Act of 1974, and the 
provisions of parts A and C of title XXVII of the Public Health Service 
Act''.

Answer:
Equity in Fertility Coverage Act of 2001 - Amends the Public Health Service Act, the Employee Retirement Income Security Act of 1974, and Federal law provisions concerning the Federal employees health benefits program to require health plans covering impotency medications such as Viagra to also cover fertility treatments.